JPMORGAN CHASE & CO - PASITHEA THERAPEUTICS CORP ownership

PASITHEA THERAPEUTICS CORP's ticker is and the CUSIP is 70261F103. A total of 13 filers reported holding PASITHEA THERAPEUTICS CORP in Q2 2023. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
JPMORGAN CHASE & CO ownership history of PASITHEA THERAPEUTICS CORP
ValueSharesWeighting
Q3 2023$1,439
-2.1%
3,0000.0%0.00%
Q2 2023$1,470
+47.0%
3,0000.0%0.00%
Q1 2023$1,000
+49900.0%
3,0000.0%0.00%
Q4 2022$2
-99.8%
3,000
+200.0%
0.00%
Q3 2022$1,0000.0%1,0000.0%0.00%
Q2 2022$1,0000.0%1,0000.0%0.00%
Q1 2022$1,000
-50.0%
1,0000.0%0.00%
Q4 2021$2,0001,0000.00%
Other shareholders
PASITHEA THERAPEUTICS CORP shareholders Q2 2023
NameSharesValueWeighting ↓
NAPLES GLOBAL ADVISORS, LLC 10,620$5,0950.00%
XTX Topco Ltd 10,726$5,1450.00%
MARK SHEPTOFF FINANCIAL PLANNING, LLC 3,323$1,5940.00%
Virtu Financial LLC 15,469$70.00%
ROYAL BANK OF CANADA 5,000$2,0000.00%
UBS Group AG 83$400.00%
WELLS FARGO & COMPANY/MN 151$720.00%
CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0$00.00%
GEODE CAPITAL MANAGEMENT, LLC 125,123$60,0560.00%
SUSQUEHANNA INTERNATIONAL GROUP, LLP 38,568$18,5010.00%
View complete list of PASITHEA THERAPEUTICS CORP shareholders